The immunomodulatory actions of E-type prostaglandins.

Prostaglandins (PGs) have been recognised as modulators of immune responses. This has been proved by both in vitro studies and from observations in animals and humans. Administration of prostaglandins for therapeutic purposes, however, has been hampered by their limited bioavailability and their pleiotropic effects, with resultant toxicological profile. Despite this, some success has been demonstrated in the clinic for the control of graft rejection, especially when used as part of a broader immunosuppressant regimen. Full realisation of the therapeutic potential of prostaglandins will depend on a better understanding of their mechanism of action at the cellular level. Recently, it has been appreciated that prostaglandins do not merely inhibit T-cell function, but appear to modulate the profile of lymphocyte sub-populations through regulation of cytokine synthesis and release. Recent efforts have also begun to focus on identifying prostaglandin receptor subtypes important for immune regulation and offer a means, together with targeted delivery, of utilising the immunosuppressant/anti-inflammatory effects of E-type prostaglandins in a safe and effective manner.